Thank you, Mr. Chair.
Dr. Champagne, thank you for taking the time to come and give us a picture of the situation. It is very enlightening.
I have a quick question. Since the first wave, have you or your colleagues been able to identify any patients who have had less treatable cancers because of treatment delays?